SCHEMBL9607750

SCHEMBL9607750

[C-]#[N+]c1ccc(Nc2nc(C3CCCCC3)nc(-c3ccc(C)cc3)c2OCc2ccccc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.41
PDE5A O76074 2/20 0.39
ADORA1 P30542 3/20 0.36
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
KDM1A O60341 3/20 0.34
ALOX5AP P20292 1/20 0.34
SRC P12931 1/20 0.33
CDK2 P24941 1/20 0.33
PDE10A Q9Y233 1/20 0.32
IGF1R P08069 1/20 0.32
MEN1 O00255 1/20 0.32
GBA1 P04062 1/20 0.32
KMT2A Q03164 1/20 0.32
CHRM3 P20309 1/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9607748 0.81 MEN1 (0.34) ADORA1ADORA2AMEN1GBA1KMT2A
SCHEMBL9607751 0.80 HTR2A (0.40) ALOX5PDE5AADORA1ADORA3ADORA2A
SCHEMBL9607734 0.78 ALOX5 (0.46) ALOX5PDE5AADORA1ADORA3HTR2A
SCHEMBL6919786 0.72 HTR2A (0.41) PDE5AHTR2AHTR2CHTR2BKDM1A
SCHEMBL6918626 0.71 HTR2A (0.46) ALOX5PDE5AADORA1ADORA3ADORA2A
SCHEMBL9607749 0.70 ABCG2 (0.50) PDE5AKDM1AMEN1GBA1KMT2A
SCHEMBL1233098 0.68 F9 (0.58) ALOX5PDE5AADORA1ADORA3ADORA2A
SCHEMBL9607695 0.68 F9 (0.41) MEN1KMT2ANPSR1F9F11
SCHEMBL9607659 0.66 EGFR (0.45) MEN1KMT2AF9F11F7
SCHEMBL9607731 0.65 PDE5A (0.45) PDE5AHTR2AHTR2CALOX5APPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS F9, F8, F12 ALOX5 387/4885PDE5A 761/4885ADORA1 1224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.